This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 Aug;128(3):607-11.

doi: 10.1007/s10549-010-1207-2. Epub 2010 Oct 16.

Are we missing the mTOR target in breast cancer?

Stephen R D Johnston¹

Affiliations

PMID: 20953834
DOI: 10.1007/s10549-010-1207-2

Comment

Are we missing the mTOR target in breast cancer?

Stephen R D Johnston. Breast Cancer Res Treat. 2011 Aug.

. 2011 Aug;128(3):607-11.

doi: 10.1007/s10549-010-1207-2. Epub 2010 Oct 16.

Author

Stephen R D Johnston¹

Affiliation

¹ Royal Marsden Hospital, Chelsea, London, SW3 6JJ, UK. stephen.johnston@rmh.nhs.uk

PMID: 20953834
DOI: 10.1007/s10549-010-1207-2

No abstract available

PubMed Disclaimer

Comment on

The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study.
Macaskill EJ, Bartlett JM, Sabine VS, Faratian D, Renshaw L, White S, Campbell FM, Young O, Williams L, Thomas JS, Barber MD, Dixon JM. Macaskill EJ, et al. Breast Cancer Res Treat. 2011 Aug;128(3):725-34. doi: 10.1007/s10549-010-0967-z. Epub 2010 Oct 13. Breast Cancer Res Treat. 2011. PMID: 20941539 Clinical Trial.
"Overcoming breast cancer drug resistance with mTOR inhibitors". Could it be a myth or a real possibility in the short-term future?
Margariti N, Fox SB, Bottini A, Generali D. Margariti N, et al. Breast Cancer Res Treat. 2011 Aug;128(3):599-606. doi: 10.1007/s10549-010-0986-9. Epub 2010 Oct 14. Breast Cancer Res Treat. 2011. PMID: 20945086 Review.
Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer.
Pérez-Tenorio G, Karlsson E, Waltersson MA, Olsson B, Holmlund B, Nordenskjöld B, Fornander T, Skoog L, Stål O. Pérez-Tenorio G, et al. Breast Cancer Res Treat. 2011 Aug;128(3):713-23. doi: 10.1007/s10549-010-1058-x. Epub 2010 Oct 16. Breast Cancer Res Treat. 2011. PMID: 20953835

Similar articles

Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
Leung EY, Askarian-Amiri M, Finlay GJ, Rewcastle GW, Baguley BC. Leung EY, et al. PLoS One. 2015 Jul 6;10(7):e0131400. doi: 10.1371/journal.pone.0131400. eCollection 2015. PLoS One. 2015. PMID: 26148118 Free PMC article.
A new clue to explain resistance to mTOR inhibitors.
Huang S. Huang S. Cell Cycle. 2012 Mar 1;11(5):844. doi: 10.4161/cc.11.5.19598. Epub 2012 Mar 1. Cell Cycle. 2012. PMID: 22336918 No abstract available.
[Antihormonal therapy in breast cancer and mTOR inhibitors].
Heudel PÉ, Tredan O, Ray-Coquard I, Treilleux I, Guastalla JP, Bachelot T. Heudel PÉ, et al. Bull Cancer. 2011 Dec;98(12):1431-7. doi: 10.1684/bdc.2011.1496. Bull Cancer. 2011. PMID: 22133994 French.
Everolimus: a new hope for patients with breast cancer.
Sendur MA, Zengin N, Aksoy S, Altundag K. Sendur MA, et al. Curr Med Res Opin. 2014 Jan;30(1):75-87. doi: 10.1185/03007995.2013.846253. Epub 2013 Oct 14. Curr Med Res Opin. 2014. PMID: 24050600 Review.
Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus.
Hadji P, Coleman R, Gnant M. Hadji P, et al. Crit Rev Oncol Hematol. 2013 Aug;87(2):101-11. doi: 10.1016/j.critrevonc.2013.05.015. Epub 2013 Jul 6. Crit Rev Oncol Hematol. 2013. PMID: 23838481 Review.

See all similar articles

Cited by

Still Living Better through Chemistry: An Update on Caloric Restriction and Caloric Restriction Mimetics as Tools to Promote Health and Lifespan.
Almendáriz-Palacios C, Mousseau DD, Eskiw CH, Gillespie ZE. Almendáriz-Palacios C, et al. Int J Mol Sci. 2020 Dec 3;21(23):9220. doi: 10.3390/ijms21239220. Int J Mol Sci. 2020. PMID: 33287232 Free PMC article. Review.
The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer.
Beaver JA, Park BH. Beaver JA, et al. Future Oncol. 2012 Jun;8(6):651-7. doi: 10.2217/fon.12.49. Future Oncol. 2012. PMID: 22764762 Free PMC article. Clinical Trial.
Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer.
Aggelis V, Johnston SRD. Aggelis V, et al. Drugs. 2019 Nov;79(17):1849-1866. doi: 10.1007/s40265-019-01208-8. Drugs. 2019. PMID: 31630379 Review.
Estrogenic regulation of S6K1 expression creates a positive regulatory loop in control of breast cancer cell proliferation.
Maruani DM, Spiegel TN, Harris EN, Shachter AS, Unger HA, Herrero-González S, Holz MK. Maruani DM, et al. Oncogene. 2012 Dec 6;31(49):5073-80. doi: 10.1038/onc.2011.657. Epub 2012 Jan 30. Oncogene. 2012. PMID: 22286763 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Springer
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal